Bolt Biotherapeutics amends supply agreement with EirGenix for trastuzumab biosimilar; up to $2M milestones

Bolt Biotherapeutics, Inc.

Amended supply agreement with EirGenix for bulk drug substance EG12014, a trastuzumab biosimilar used in BDC-1001 HER2 Boltbody ISAC.
Requires joint steering committee, revised forecasting/order terms, and pricing adjustments based on production scale.
Company to make up to $2.0M in milestone payments upon regulatory achievements for HER2 Boltbody ISAC.
Agreement remains effective as long as Bolt or affiliates continue development/commercialization of the ISAC product.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.